Ozaslan, E. Et Al. 2017. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less. ANTI-CANCER DRUGS , vol.28, no.2 , 222-229.

Ozaslan, E., Karaca, H., Koca, S., Sevinc, A., Hacioglu, B., ÖZKAN, M., ... Ozcelik, M.(2017). Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less. ANTI-CANCER DRUGS , vol.28, no.2, 222-229.

Ozaslan, Ersin Et Al. "Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less," ANTI-CANCER DRUGS , vol.28, no.2, 222-229, 2017

Ozaslan, Ersin Et Al. "Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less." ANTI-CANCER DRUGS , vol.28, no.2, pp.222-229, 2017

Ozaslan, E. Et Al. (2017) . "Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less." ANTI-CANCER DRUGS , vol.28, no.2, pp.222-229.

@article{article, author={Ersin ÖZASLAN Et Al. }, title={Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less}, journal={ANTI-CANCER DRUGS}, year=2017, pages={222-229} }